All Oncology News

Ajjai Shivaram Alva, MBBS, highlights ongoing advances made in the treatment of patients with metastatic renal cell carcinoma.

Frontline maintenance therapy with avelumab plus best supportive care demonstrated a statistically significant improvement in overall survival compared with best supportive care alone in patients with previously untreated locally advanced or metastatic urothelial carcinoma, regardless of PD-L1 expression.

Afonso Ribeiro, MD, discusses imaging modalities as well as challenges and future goals for the pancreatic cancer paradigm.

Kaushal Parikh, MD, MBBS, reflects on pivotal lung cancer data shared at recent major oncology meetings.

Mike Cusnir, MD, discusses the evolving gastric cancer paradigm.

Clara Hwang, MD, discusses key trials that have shaped the current treatment paradigms of metastatic castration-sensitive prostate cancer and metastatic castration-resistant prostate cancer.

Poziotinib did not meet its primary endpoint of overall response rate in patients with previously treated EGFR-mutant non–small cell lung cancer who have exon 20 insertion mutations.

In the first 11 months following the FDA approval of the CDK4/6 inhibitor abemaciclib as a single agent and in combination with endocrine therapy for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer, it is being used heterogeneously, including in patients with characteristics indicative of worse prognosis.

The FDA has accepted a biologics license application to review eflapegrastim for the management of chemotherapy-induced neutropenia.

Ulka Vaishampayan, MD, discusses the role of frontline immunotherapy and patient selection in metastatic renal cell carcinoma. 

Nathan Pennell, MD, PhD, discusses the emerging widespread role of liquid biopsies in lung cancer and how to best utilize the approach in clinical practice.

The FDA has approved olaparib for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma.

The FDA has accepted a biologics license application for sacituzumab govitecan as a treatment for patients with metastatic triple-negative breast cancer who have received at least 2 prior therapies for metastatic disease.

Jean L. Koff, MD, MS, highlights exciting advances made in follicular lymphoma and the promise of CAR T-cell therapies in other lymphoma subtypes.

William G. Blum, MD, discusses the introduction of novel agents into acute myeloid leukemia treatment and how this is impacting the role of molecular testing for patients.

An application has been submitted to the FDA for selinexor for the treatment of patients with relapsed/refractory diffuse large B-Cell lymphoma who have received at least 2 prior multiagent therapies and who are ineligible for stem cell transplantation, including CAR T-cell therapy.

The FDA has granted a Regenerative Medicine Advanced Therapy designation to ADP-A2M4 (MAGE-A4) as a treatment for patients with synovial sarcoma.

The FDA has granted fast track designation to the potent reversible LSD1 inhibitor SP-2577 (seclidemstat) for the treatment of relapsed/refractory patients with Ewing sarcoma.

Michael Wang, MD, discusses the ZUMA-2 trial and the potential impact of CAR T-cell therapy on the treatment paradigm in mantle cell lymphoma.

Julie R. Gralow, MD, discusses the emergence of biosimilars in the United States and globally.

Induction therapy with R-CHOP followed by maintenance rituximab continued to show improvements in survival and responses compared with R-CHOP and interferon-alpha maintenance in older patients with mantle cell lymphoma.

A new drug application has been submitted to the FDA for tucatinib for use in combination with trastuzumab and capecitabine for the treatment of patients with unresectable locally advanced or metastatic HER2-positive breast cancer.

Minimal residual disease has become an important investigational prognostic marker and risk stratification tool in acute lymphoblastic leukemia.

Ajay K. Nooka, MD, MPH, FACP, discusses the shift in induction regimens in multiple myeloma and the impact of daratumumab (Darzalex) on the space.

Faculty from Memorial Sloan Kettering Cancer Center shed light on some of the intriguing research in hematologic cancer being conducted at their institution.

Japan’s Pharmaceuticals and Medical Devices Agency has approved the combination of pembrolizumab and axitinib for the first-line treatment of patients with radically unresectable or metastatic renal cell carcinoma.

The FDA has granted an accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ≥2 prior anti–HER2-based regimens in the metastatic setting.

Brian A. Van Tine, MD, PhD, discusses the results of a phase I study looking at the effects of ADP-A2M4 in patients with synovial sarcoma.

Japan's Pharmaceuticals and Medical Devices Agency has granted approval to frontline pembrolizumab as monotherapy and in combination with chemotherapy for the treatment of patients with recurrent or distant metastatic head and neck cancer.

A biologics license application has been submitted to the FDA for margetuximab for use in combination with chemotherapy as a treatment for patients with metastatic HER2-positive breast cancer.